ARTES attends European Animal Health Investment Forum

ARTES will head for London’s elite May­fair dis­trict in Feb­ru­ary to take part in the ‘Drag­ons Den’ of vet­eri­nary med­i­cine, the Euro­pean Ani­mal Health Invest­ment Forum.

This will be ARTES’ first par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event.

ARTES will be rep­re­sent­ed by its Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, who will be talk­ing in par­tic­u­lar about the devel­op­ment of its inno­v­a­tive pro­pri­etary vac­cine devel­op­ment plat­form, METAVAX®.


METAVAX® gen­er­ates vac­cines based on the WHO-rec­om­mend­ed yeast organ­ism Hansenu­la poly­mor­pha.

ARTES Biotech­nol­o­gy also has exper­tise in human and ani­mal vac­cine devel­op­ment and is col­lab­o­rat­ing with ani­mal health leader Boehringer Ingel­heim to devel­op  a vac­cine based on Hansenu­la poly­mor­pha expres­sion, com­bined with the METAVAX® plat­form

Self-adjuvanting vaccines

We look for­ward to attend­ing the Euro­pean Ani­mal Health Invest­ment Forum for the oppor­tu­ni­ty to net­work with CEOs, busi­ness devel­op­ers and sci­en­tists from vet­eri­nary phar­ma­ceu­ti­cal com­pa­nies inter­est­ed in devel­op­ment of high­ly immuno­genic vac­cines,” com­ment­ed Dr. Pio­ntek.

This is a great oppor­tu­ni­ty to find new con­tacts, refresh old ones and show how we have devel­oped an eco­nom­i­cal approach for low-cost mass pro­duc­tion of safe, effec­tive and self-adju­vant­i­ng vac­cines,” said Dr. Pio­ntek.

ARTES will also use the meet­ing to share knowl­edge about its VLP tech­nol­o­gy for anti­gen pre­sen­ta­tion and oth­er vac­cine tech­nolo­gies.  It will also exchange infor­ma­tion on its spe­cial­ist cell lines and process devel­op­ment for bio-phar­ma­ceu­ti­cal prod­ucts.

Meet us at the Ani­mal Health Invest­ment in Lon­don, 22nd and 23rd Feb­ru­ary, at the Mil­len­ni­um Lon­don May­fair Hotel or con­tact us pre­vi­ous­ly for a per­son­al meet­ing! We look for­ward to meet­ing you!

ARTES and BioSun announce co-development for HPV vaccine

Lan­gen­feld, Ger­many / Tehran, Iran  

ARTES Biotech­nol­o­gy and Bio­Sun Pharmed announced to join forces for the devel­op­ment and man­u­fac­tur­ing of a HPV (human papil­lo­ma virus) vac­cine in Iran.

The agreed long-term col­lab­o­ra­tion involved the strength of both part­ners. ARTES Biotech­nol­o­gy GmbH (ARTES) is spe­cial­ized in cell line and process devel­op­ment of virus like par­ti­cle (VLP) based vac­cines and in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal­ly rel­e­vant pro­duc­tion process­es.

Bio­Sun Pharmed Co is involved in the man­u­fac­tur­ing of high qual­i­ty and safe vac­cines and bio­phar­ma­ceu­ti­cal prod­ucts for the domes­tic and inter­na­tion­al mar­kets.

Human papil­lo­ma virus infec­tion (HPV) is the most com­mon sex­u­al­ly trans­mit­ted infec­tion glob­al­ly. Most peo­ple are infect­ed at some point in their lives. There are approx­i­mate­ly 79 mil­lion men/women active­ly infect­ed with the virus at any point in time. Annu­al­ly, there are 14 mil­lion new­ly diag­nosed cas­es of HPV. HPV infec­tion can cause in warts or pre­can­cer­ous lesions. The pre­can­cer­ous lesions increase the risk of can­cer.

In 2012, about 270,000 women died from cer­vi­cal can­cer, more than 85% of these deaths occur­ring in low and mid­dle income coun­tries.

We are extreme­ly delight­ed about the mutu­al­ly agreed col­lab­o­ra­tion. This agree­ment is the next step in ARTES’ strat­e­gy to devel­op from a ser­vice provider for process devel­op­ment to a part­ner for full phar­ma­ceu­ti­cal prod­uct devel­op­ment,” Dr. Michael Pio­ntek, founder and man­ag­ing direc­tor of ARTES Biotech­nol­o­gy.

For the first time, ARTES will be respon­si­ble for process devel­op­ment of API, for­mu­la­tion, qual­i­ty con­trol and sup­ply of pre­clin­i­cal test mate­r­i­al. In addi­tion, ARTES will be engaged in design of the man­u­fac­tur­ing site at Bio­Sun and in selec­tion of third par­ties for GMP man­u­fac­tur­ing.

I am real­ly pleased that after tech­ni­cal and com­mer­cial dis­cus­sions, we could final­ly make col­lab­o­ra­tion agree­ment with a well-known and reli­able part­ner for not only pro­duc­ing pre-mas­ter cell banks but also for co-devel­op­ments of our mutu­al inter­est­ed prod­ucts. Our mis­sion is pro­duc­ing high qual­i­ty and afford­able vac­cines and biotech prod­ucts improv­ing health lev­el of com­mu­ni­ty.” Dr. Moham­mad Tagha­vian, man­ag­ing direc­tor of Bio­sun Pharmed.

Finan­cial details of this agree­ment were not dis­closed.

Sun Pharma & ICGEB sign exclusive deal on dengue vaccine — ARTES adds experience in VLP development and production

NEW DELHI, India I Octo­ber 19, 2016

Inter­na­tion­al Cen­tre for Genet­ic Engi­neer­ing and Biotech­nol­o­gy (ICGEB) and Sun Phar­ma today announced their new col­lab­o­ra­tion for devel­op­ment of a dengue vac­cine, tar­get­ed against all the four serotypes of Dengue virus that cause dis­ease in humans. ICGEB has devel­oped a tai­lored recom­bi­nant virus-like-par­ti­cle (VLP) based tetrava­lent dengue vac­cine, con­tain­ing host-recep­tor bind­ing domain of enve­lope pro­tein of all the four DENV serotypes. ICGEB has con­duct­ed pre-clin­i­cal stud­ies over the past sev­en years and devel­oped the exist­ing Know-How and Patents for this dengue vac­cine can­di­date.

Sun Phar­ma invests over US$ 300 mil­lion annu­al­ly on research and devel­op­ment in phar­ma­ceu­ti­cals and bio­log­ics. The Com­pa­ny will use its in-house exper­tise as well as exper­tise of its Asso­ciate com­pa­ny, ARTES Biotech­nol­o­gy GmbH, in devel­op­ment of dengue vac­cine. ARTES will add their expe­ri­ence and pro­pri­etary know-how in pro­duc­tion of VLP based vac­cines from yeast pro­duc­tion cell lines. Hep‑B and HPV vac­cines devel­oped by ARTES are licensed to sev­er­al com­pa­nies world­wide and a Malar­ia vac­cine pro­gram is spon­sored by PATH (Malar­ia Vac­cine Ini­tia­tive). Tak­en togeth­er, the Com­pa­ny has past expe­ri­ence in devel­op­ment of Hep‑B and Typhoid vac­cines, as well as com­plex vac­cines, such as HPV and Malar­ia.


For the full text, see:

ARTES and Burnet Institute join forces to develop novel hepatitis C vaccine

ARTES Biotech­nol­o­gy and Bur­net Insti­tute announce they have joined forces to devel­op a nov­el, effec­tive vac­cine to pre­vent trans­mis­sion of hepati­tis C virus (HCV).

An HCV vac­cine is urgent­ly need­ed to pre­vent re-infec­tion in peo­ple treat­ed through antivi­ral ther­a­pies and reverse the high glob­al mor­tal­i­ty rates from infec­tion-relat­ed liv­er cir­rho­sis or liv­er can­cer, esti­mat­ed by the World Health Orga­ni­za­tion (WHO) to be more than 500,000 peo­ple each year. More than 130 mil­lion peo­ple glob­al­ly are car­ri­ers of HCV, a blood-borne virus.

The inno­v­a­tive hepati­tis C vac­cine project will com­bine Bur­nets’ pro­pri­etary HepSeeVaxDelta3™ tech­nol­o­gy, devel­oped by Asso­ciate Pro­fes­sor Hei­di Drum­mer and col­leagues, with ARTES’ pro­pri­etary METAVAX® tech­nol­o­gy for the devel­op­ment of chimeric virus-like par­ti­cle (VLP) based vac­cines. The project aims to devel­op a VLP based vac­cine that effi­cient­ly presents HCV anti­gens to pre­vent hepati­tis C infec­tion. The VLPs will present the nov­el, mod­i­fied enve­lope pro­tein (E2) on its sur­face, there­by tar­get­ing the vac­cine to den­drit­ic cells to prime and pre­pare the immune sys­tem to fight against hepati­tis C infec­tion.

Deputy Head of Burnet’s Cen­tre for Bio­med­ical Research and HCV vac­cine team leader, Asso­ciate Pro­fes­sor Drum­mer said HepSeeVaxDelta3™ tech­nol­o­gy over­comes a crit­i­cal lim­i­ta­tion to HCV vac­cine devel­op­ment. “The virus that caus­es HCV has evolved to avoid the immune sys­tem so that in nat­ur­al infec­tion, key immune respons­es are delayed or dis­tract­ed by irrel­e­vant tar­gets on the virus. The same is true for con­ven­tion­al vac­cine plat­forms test­ed pre­vi­ous­ly. The HepSeeVaxDelta3™ com­po­nent of the vac­cine redi­rects the immune response to make anti­bod­ies on the most impor­tant tar­gets that pre­vent infec­tion against the sev­en cir­cu­lat­ing HCV geno­types.”

Man­ag­ing Direc­tor of ARTES, Dr Michael Pio­ntek said his com­pa­ny was excit­ed to join forces with Bur­net Insti­tute to devel­op a much-need­ed vac­cine against hepati­tis C, which is endem­ic in many coun­tries where treat­ment costs are high and HCV pos­es a sig­nif­i­cant bur­den on health­care sys­tems. “Access to diag­no­sis and treat­ment is lim­it­ed, espe­cial­ly in endem­ic coun­tries in Africa and Asia, so there is a strong demand for a safe and low-cost vac­cine to pre­vent hepati­tis C infec­tion. This is in-line with the aim of the WHO to real­ize their hepati­tis C elim­i­na­tion tar­gets. After out-licens­ing process­es for hepati­tis B vac­cine pro­duc­tion world­wide, ARTES is proud to take the next step togeth­er with Bur­net Insti­tute in fight­ing anoth­er life-threat­en­ing hepati­tis infec­tion.”


The vac­cine devel­op­ment plat­form

ARTES’ vac­cine devel­op­ment plat­form METAVAX® in com­bi­na­tion with the expres­sion host Hansenu­la poly­mor­pha (rec­om­mend­ed by the WHO for hepati­tis B vac­cine pro­duc­tion) is the pre­ferred tool for the devel­op­ment of afford­able vac­cines. ARTES’ devel­op­ment plat­form is a unique and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines.

Bur­net Institute’s HepSeeVaxDelta3™ tech­nol­o­gy is devel­oped by re-engi­neer­ing the major HCV viral sur­face pro­tein E2 to pro­duce the nov­el HepSeeVaxDelta3™ vac­cine. HepSeeVaxDelta3™ can gen­er­ate high lev­els of anti­bod­ies that can block repli­ca­tion of all sev­en geno­types of HCV in lab­o­ra­to­ry tests. This major sci­en­tif­ic advance offers the prospect of a sim­ple, uni­ver­sal vac­cine to pre­vent HCV infec­tion world­wide.

ARTES and Biosphere announce collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in micro­bial cell line and process devel­op­ment for recom­bi­nant pro­tein pro­duc­tion and tech­nol­o­gy provider for high-qual­i­ty biotech­no­log­i­cal process­es, join forces with the well-estab­lished con­tract man­u­fac­tur­ing com­pa­ny Bios­phere. Aim of this pre­ferred coop­er­a­tion is to offer a full range of ser­vices, start­ing from cell line gen­er­a­tion up to indus­tri­al scale man­u­fac­tur­ing in one pack­age. The com­bi­na­tion of the dif­fer­ent exper­tise, know-how and infra­struc­ture of the two com­pa­nies will flow direct­ly into one com­mon offer. This offer address­es cus­tomers who are look­ing for devel­op­ment of enzymes and pro­teins cur­rent­ly applied in the phar­ma­ceu­ti­cal, food and fine chem­i­cal sec­tor.

ARTES offers manufacturing of preclinical samples up to multi-gram scale

ARTES Biotech­nol­o­gy, spe­cial­ized in micro­bial cell line and process devel­op­ment for the phar­ma­ceu­ti­cal indus­try recent­ly expand­ed its ser­vice port­fo­lio and sup­plied sam­ples for pre­clin­i­cal test­ing to a first client.

With the new equipped pilot plant for pro­duc­tion of nonGMP mate­r­i­al, we are now in the posi­tion to pro­vide our clients with high qual­i­ty pre­clin­i­cal test mate­r­i­al in gram amounts”, Michael Weniger Head of Process Devel­op­ment at ARTES stat­ed. “Thanks to our exist­ing expe­ri­ence, instal­la­tion of the plant at ARTES, imple­men­ta­tion of a new process and sup­ply of a batch have been man­aged with­in three months. The chal­lenge in this kind of fast track projects is very often to meet a high qual­i­ty stan­dard”, Weniger point­ed out.


For more detailed infor­ma­tion and for an offer please con­tact us.

ARTES and Boehringer Ingelheim Animal Health Announce Collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in recom­bi­nant pro­tein pro­duc­tion, process and vac­cine devel­op­ment from micro­bial expres­sion sys­tems announces a col­lab­o­ra­tion with the glob­al phar­ma­ceu­ti­cal com­pa­ny Boehringer Ingel­heim Ani­mal Health.

ARTES’ expres­sion sys­tem Hansenu­la poly­mor­pha is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and rec­om­mend­ed by the World Health Orga­ni­za­tion (WHO) for these pur­pos­es. In com­bi­na­tion with ARTESMETAVAX® plat­form, this offers a new, unique and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines required in the vet­eri­nary field.

This col­lab­o­ra­tion is anoth­er mile­stone in expand­ing our vac­cine devel­op­ment exper­tise”, Michael Pio­ntek, man­ag­ing direc­tor of ARTES stat­ed. “We are more than con­fi­dent that our tech­nol­o­gy plat­form is per­fect­ly suit­ed for the devel­op­ment of safe and cost effi­cient vac­cines that are high­ly rel­e­vant for the vet­eri­nary mar­ket.”

Part­ner­ing is a cen­tral part of our strat­e­gy. We are excit­ed about this col­lab­o­ra­tion and the oppor­tu­ni­ty to devel­op more inno­v­a­tive vac­cines for the ani­mal health mar­ket,” says Rolf-Dieter Gün­ther, Head of Glob­al Busi­ness Devel­op­ment and Licens­ing Ani­mal Health for Boehringer Ingel­heim.

ARTES, instrAction and Q‑Biologicals Join Forces for Veterinary Vaccine Development

Under the title:” devel­op­ment of a virus-like-par­ti­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions”, in short “Pluri­vax”, the EU coop­er­a­tion is part of the recent 8th Euro­Trans­Bio call and will be fund­ed for a three year peri­od sup­port­ed by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) and the Flan­ders (Bel­gium) agency for Inno­va­tion by Sci­ence and Tech­nol­o­gy (IWT).

The intent of “Pluri­vax” is to devel­op a sta­ble pro­duc­tion plat­form and an adapt­ed high-qual­i­ty process to have an effec­tive and usable inte­grat­ed best prac­tice suit­able for sev­er­al vet­eri­nary vaccines.The plat­form result­ing from this project will be the first of its kind in vet­eri­nary appli­ca­tion and thus opens access to a huge mar­ket. A robust, inex­pen­sive vac­cine will reduce the need for antibi­ot­ic treat­ment of food ani­mals, there­by direct­ly reduc­ing pro­duc­tion costs and improv­ing qual­i­ty of life for the food ani­mal itself and for the con­sumer.

ARTES VLP plat­form METAVAX® has already been applied to the devel­op­ment of adju­vant-free vac­cines against dif­fer­ent dis­eases like avian and swine flu, malar­ia and HIV. Our yeast expres­sion host Hansenu­la is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for mass vac­ci­na­tions. Togeth­er, our plat­forms build an excel­lent approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines”, Michael Pio­ntek, Man­ag­ing Direc­tor of ARTES.

Annie Van Broekhoven, CEO Q‑Biologicals com­ments: “We will employ our know-how and exper­tise in the field of bio­process devel­op­ment, man­u­fac­tur­ing and for­mu­la­tion of recom­bi­nant anti­gens to devel­op a robust pro­duc­tion process for VLP based vac­cines. We are con­fi­dent that we will suc­ceed in short­en­ing the process devel­op­ment times con­sid­er­ably, and in doing so dri­ve down devel­op­ment costs and sup­port rapid mar­ket intro­duc­tion.”

We will con­tribute our tai­lor made but com­pet­i­tive­ly priced plat­form purifi­ca­tion process to this cost sen­si­tive pro­duc­tion process­es. Our pro­pri­etary chro­matog­ra­phy phase tech­nol­o­gy, already being used for purifi­ca­tion of com­mer­cial bio­phar­ma­ceu­ti­cals and small mol­e­cule APIs, allows spe­cif­ic bind­ing of tar­get mol­e­cules and can be trans­ferred to almost every chro­mato­graph­ic car­ri­er sub­strate”, Peter Kallien, CFO of instrAc­tion.

Malaria transmission-blocking vaccines – ARTES and Burnet announced a development project

ARTES Biotech­nol­o­gy and Bur­net Insti­tute have joined forces to devel­op a new type of malar­ia vac­cine in a project fund­ed by the PATH Malar­ia Vac­cine Ini­tia­tive (MVI).

The project will use excit­ing nov­el tech­nol­o­gy devel­oped at the Bur­net Insti­tute. ARTES holds the inter­na­tion­al patent rights and adapt­ed the plat­form to vac­cine pro­duc­tion (known as the Metavax® plat­form).

Puri­fied vac­cine anti­gens (Pfs25 and Pfs230) will be pro­duced as virus-like par­ti­cles (VLPs, a type of nano-par­ti­cle) for test­ing in lab­o­ra­to­ry stud­ies. The VLPs will be tak­en up by immune cells to prime and pre­pare the immune sys­tem to fight malar­ia.

The project will focus on strate­gies to pro­duce vac­cines that can block the trans­mis­sion of malar­ia infec­tion from mos­qui­toes to peo­ple, as part of a pro­gram fund­ed by MVI.

Strategic cooperation between ARTES & Sun Pharma

ARTES Biotech­nol­o­gy has entered into a strate­gic col­lab­o­ra­tion with a sub­sidiary of Sun Phar­ma­ceu­ti­cal Indus­tries Ltd, an inter­na­tion­al spe­cial­ty phar­ma­ceu­ti­cal com­pa­ny with a diver­si­fied prod­uct port­fo­lio head­quar­tered in Mumbai/India.

This step broad­ens ARTES’ inter­na­tion­al client base and demon­strates its abil­i­ty to attract blue chip phar­ma­ceu­ti­cal com­pa­nies. Under the col­lab­o­ra­tion agree­ment, ARTES will be respon­si­ble to deliv­er top-class cell lines and pro­duc­tion process­es for sev­er­al phar­ma­ceu­ti­cal tar­gets.

As part of the strate­gic col­lab­o­ra­tion, Sun Phar­ma’s sub­sidiary will also become a minor­i­ty share­hold­er in ARTES.